171 related articles for article (PubMed ID: 27214077)
1. Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis.
Christopeit M; Badbaran A; Zabelina T; Zeck G; Fehse B; Ayuk F; Wolschke C; Kröger N
Bone Marrow Transplant; 2016 Oct; 51(10):1391-1393. PubMed ID: 27214077
[No Abstract] [Full Text] [Related]
2. Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.
Panagiota V; Thol F; Markus B; Fehse B; Alchalby H; Badbaran A; Lehmann U; Koenecke C; Shahswar R; Chaturvedi A; Stadler M; Eder M; Göhring G; Koenigsmann M; Kloos A; Trummer A; Schroeder T; Kobbe G; Thiede C; Platzbecker U; Schlegelberger B; Kreipe HH; Ganser A; Kröger N; Heuser M
Leukemia; 2014 Jul; 28(7):1552-5. PubMed ID: 24504025
[No Abstract] [Full Text] [Related]
3. Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell transplantation.
Haslam K; Langabeer SE; Molloy K; McMullin MF; Conneally E
Br J Haematol; 2014 Sep; 166(5):800-2. PubMed ID: 24749731
[No Abstract] [Full Text] [Related]
4. Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis.
Lissandre S; Bay JO; Cahn JY; Porcher R; Cacheux V; Cabrespine A; Cornillon J; Cassinat B; Peffault de Latour R; Socie G; Robin M
Bone Marrow Transplant; 2011 Apr; 46(4):557-61. PubMed ID: 21042309
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience.
Schmohl JU; Groh C; Faul C; Vogel W; Möhle R; Wirths S; Schneidawind D; Kanz L; Bethge WA
Ann Hematol; 2016 May; 95(6):973-83. PubMed ID: 27021303
[TBL] [Abstract][Full Text] [Related]
6. Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation.
Kröger N; Panagiota V; Badbaran A; Zabelina T; Triviai I; Araujo Cruz MM; Shahswar R; Ayuk F; Gehlhaar M; Wolschke C; Bollin R; Walter C; Dugas M; Wiehlmann L; Lehmann U; Koenecke C; Chaturvedi A; Alchalby H; Stadler M; Eder M; Christopeit M; Göhring G; Koenigsmann M; Schlegelberger B; Kreipe HH; Ganser A; Stocking C; Fehse B; Thol F; Heuser M
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1095-1101. PubMed ID: 28389256
[TBL] [Abstract][Full Text] [Related]
7. SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation.
Bartels S; Lehmann U; Büsche G; Schlue J; Mozer M; Stadler J; Triviai I; Alchalby H; Kröger N; Kreipe H
Leukemia; 2015 Jan; 29(1):253-5. PubMed ID: 25231745
[No Abstract] [Full Text] [Related]
8. A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis.
Gupta V; Kröger N; Aschan J; Xu W; Leber B; Dalley C; Sabloff M; Lipton JH; Messner H; Brune M
Bone Marrow Transplant; 2009 Sep; 44(5):317-20. PubMed ID: 19234505
[No Abstract] [Full Text] [Related]
9. Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.
Slot S; Smits K; van de Donk NW; Witte BI; Raymakers R; Janssen JJ; Broers AE; Te Boekhorst PA; Zweegman S
Bone Marrow Transplant; 2015 Nov; 50(11):1424-31. PubMed ID: 26237165
[TBL] [Abstract][Full Text] [Related]
10. Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.
Robin M; Porcher R; Wolschke C; Sicre de Fontbrune F; Alchalby H; Christopeit M; Cassinat B; Zabelina T; Peffault de Latour R; Ayuk F; Socié G; Kröger N
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1206-1211. PubMed ID: 26970380
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years.
Daghia G; Zabelina T; Zeck G; von Pein UM; Christopeit M; Wolschke C; Ayuk F; Kröger N
Eur J Haematol; 2019 Oct; 103(4):370-378. PubMed ID: 31306511
[TBL] [Abstract][Full Text] [Related]
12. Progression of
Holmström MO; Novotny GW; Petersen J; Aaboe-Jørgensen M; Hasselbalch HC; Andersen MH; Nielsen SL; Fassi DE; Schöllkopf C
Leuk Lymphoma; 2019 Dec; 60(13):3296-3299. PubMed ID: 31256699
[No Abstract] [Full Text] [Related]
13. Reduced intensity allogeneic stem cell transplantation for younger patients with myelofibrosis.
Mannina D; Zabelina T; Wolschke C; Heinzelmann M; Triviai I; Christopeit M; Badbaran A; Bonmann S; von Pein UM; Janson D; Ayuk F; Kröger N
Br J Haematol; 2019 Aug; 186(3):484-489. PubMed ID: 31090920
[TBL] [Abstract][Full Text] [Related]
14. Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT.
McLornan DP; Szydlo R; Robin M; van Biezen A; Koster L; Blok HJP; Van Lint MT; Finke J; Vitek A; Carlson K; Griskevicius L; Holler E; Itälä-Remes M; Schaap M; Socié G; Bay JO; Beguin Y; Bruno B; Cornelissen JJ; Gedde-Dahl T; Ljungman P; Rubio MT; Yakoub-Agha I; Klyuchnikov E; Olavarria E; Chalandon Y; Kröger N
Br J Haematol; 2018 Aug; 182(3):418-422. PubMed ID: 29808926
[TBL] [Abstract][Full Text] [Related]
15. Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis.
Szuber N; Lasho TL; Finke C; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Tefferi A
Leukemia; 2019 Mar; 33(3):780-785. PubMed ID: 30315236
[No Abstract] [Full Text] [Related]
16. Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation.
Badbaran A; Fehse B; Christopeit M; Aranyossy T; Ayuk FA; Wolschke C; Kröger N
Bone Marrow Transplant; 2016 Jun; 51(6):872-3. PubMed ID: 26878663
[No Abstract] [Full Text] [Related]
17. Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
McLornan D; Szydlo R; Koster L; Chalandon Y; Robin M; Wolschke C; Beelen D; Socié G; Bornhäuser M; Angelucci E; Niederwieser D; Gerbitz A; Finke J; Vitek A; Itälä-Remes M; Radujkovic A; Kanz L; Potter V; Chevallier P; Stelljes M; Petersen E; Robinson S; Poiré X; Klyuchnikov E; Hernández-Boluda JC; Czerw T; Hayden P; Kröger N; Yakoub-Agha I
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2167-2171. PubMed ID: 31284069
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk.
Nivison-Smith I; Dodds AJ; Butler J; Bradstock KF; Ma DD; Simpson JM; Szer J
Biol Blood Marrow Transplant; 2012 Feb; 18(2):302-8. PubMed ID: 21620988
[TBL] [Abstract][Full Text] [Related]
19. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.
Ali H; Aldoss I; Yang D; Mokhtari S; Khaled S; Aribi A; Afkhami M; Al Malki MM; Cao T; Mei M; O'Donnell M; Salhotra A; Pullarkat V; Yang L; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pillai R; Snyder D
Blood Adv; 2019 Jan; 3(1):83-95. PubMed ID: 30622146
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution.
Nishihori T; Perkins J; Kim J; Field T; Pidala J; Roman-Diaz J; Komrokji RS; Fernandez HF; Anasetti C; Kharfan-Dabaja MA
Am J Hematol; 2010 Nov; 85(11):904-7. PubMed ID: 20890908
[No Abstract] [Full Text] [Related]
[Next] [New Search]
